Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data

BACKGROUND: Since the results of the ToGA trial were published, trastuzumab-based chemotherapy has been used as the standard first-line treatment for HER2-positive recurrent or primary metastatic gastric cancer (RPMGC). However, the real-world data has been rarely reported. Therefore, we investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae-Hwan, Do Cho, Hun, Choi, Yong Won, Lee, Hyun Woo, Kang, Seok Yun, Jeong, Geum Sook, Choi, Jin-Hyuk, Ahn, Mi Sun, Sheen, Seung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995795/
https://www.ncbi.nlm.nih.gov/pubmed/33771119
http://dx.doi.org/10.1186/s12885-021-08058-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995795/
https://www.ncbi.nlm.nih.gov/pubmed/33771119
http://dx.doi.org/10.1186/s12885-021-08058-2

Ejemplares similares